FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2516657840> ?p ?o ?g. }

• W2516657840 endingPage "1473" @default.
• W2516657840 startingPage "1467" @default.
• W2516657840 abstract "Transplantation of human muscle precursor cells (hMPCs) is envisioned for the treatment of various muscle diseases. However, a feasible noninvasive tool to monitor cell survival, migration, and integration into the host tissue is still missing. <b>Methods:</b> In this study, we designed an adenoviral delivery system to genetically modify hMPCs to express a signaling-deficient form of human dopamine D₂ receptor (hD2R). The gene expression levels of the receptor were evaluated by reverse transcriptase polymerase chain reaction, and infection efficiency was evaluated by fluorescent microscopy. The viability, proliferation, and differentiation capacity of the transduced cells, as well as their myogenic phenotype, were determined by flow cytometry analysis and fluorescent microscopy. ¹⁸F-fallypride and ¹⁸F-fluoromisonidazole, two well-established PET radioligands, were assessed for their potential to image engineered hMPCs in a mouse model and their uptakes were evaluated at different time points after cell inoculation in vivo. Biodistribution studies, autoradiography, and PET experiments were performed to determine the extent of signal specificity. To address feasibility for tracking hMPCs in an in vivo model, the safety of the adenoviral gene delivery was evaluated. Finally, the harvested tissues were histologically examined to determine whether survival of the transplanted cells was sustained at different time points. <b>Results:</b> Adenoviral gene delivery was shown to be safe, with no detrimental effects on the primary human cells. The viability, proliferation, and differentiation capacity of the transduced cells were confirmed, and flow cytometry analysis and fluorescent microscopy showed that their myogenic phenotype was sustained. ¹⁸F-fallypride and ¹⁸F-fluoromisonidazole were successfully synthesized. Specific binding of ¹⁸F-fallypride to hD2R hMPCs was demonstrated in vitro and in vivo. Furthermore, the ¹⁸F-fluoromisonidazole signal was high at the early stages. Finally, sustained survival of the transplanted cells at different time points was confirmed histologically, with formation of muscle tissue at the site of injection. <b>Conclusion:</b> Our proposed use of a signaling-deficient hD2R as a potent reporter for in vivo hMPC PET tracking by ¹⁸F-fallypride is a significant step toward potential noninvasive tracking of hD2R hMPCs and bioengineered muscle tissues in the clinic." @default.
• W2516657840 created "2016-09-16" @default.
• W2516657840 creator A5008600645 @default.
• W2516657840 creator A5009932633 @default.
• W2516657840 creator A5020272191 @default.
• W2516657840 creator A5021236744 @default.
• W2516657840 creator A5028663673 @default.
• W2516657840 creator A5041743198 @default.
• W2516657840 creator A5047331691 @default.
• W2516657840 creator A5056329041 @default.
• W2516657840 creator A5064358886 @default.
• W2516657840 creator A5068214093 @default.
• W2516657840 creator A5071312640 @default.
• W2516657840 date "2016-05-19" @default.
• W2516657840 modified "2023-10-14" @default.
• W2516657840 title "Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering" @default.
• W2516657840 cites W1486038294 @default.
• W2516657840 cites W1908383608 @default.
• W2516657840 cites W1970714110 @default.
• W2516657840 cites W1990152869 @default.
• W2516657840 cites W1994605120 @default.
• W2516657840 cites W1996223992 @default.
• W2516657840 cites W2000341470 @default.
• W2516657840 cites W2004736524 @default.
• W2516657840 cites W2012034491 @default.
• W2516657840 cites W2020585068 @default.
• W2516657840 cites W2020697903 @default.
• W2516657840 cites W2026180033 @default.
• W2516657840 cites W2030973598 @default.
• W2516657840 cites W2033211184 @default.
• W2516657840 cites W2043354767 @default.
• W2516657840 cites W2064671909 @default.
• W2516657840 cites W2067062808 @default.
• W2516657840 cites W2069901076 @default.
• W2516657840 cites W2087604644 @default.
• W2516657840 cites W2087694306 @default.
• W2516657840 cites W2092518988 @default.
• W2516657840 cites W2092627579 @default.
• W2516657840 cites W2100744265 @default.
• W2516657840 cites W2113502176 @default.
• W2516657840 cites W2114211204 @default.
• W2516657840 cites W2128650326 @default.
• W2516657840 cites W2141980545 @default.
• W2516657840 cites W2160416006 @default.
• W2516657840 cites W2163660141 @default.
• W2516657840 cites W2165018909 @default.
• W2516657840 cites W2270313929 @default.
• W2516657840 cites W2316364216 @default.
• W2516657840 cites W2320749841 @default.
• W2516657840 cites W2325905945 @default.
• W2516657840 cites W2503582067 @default.
• W2516657840 doi "https://doi.org/10.2967/jnumed.115.170548" @default.
• W2516657840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5130147" @default.
• W2516657840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27199355" @default.
• W2516657840 hasPublicationYear "2016" @default.
• W2516657840 type Work @default.
• W2516657840 sameAs 2516657840 @default.
• W2516657840 citedByCount "11" @default.
• W2516657840 countsByYear W25166578402016 @default.
• W2516657840 countsByYear W25166578402017 @default.
• W2516657840 countsByYear W25166578402018 @default.
• W2516657840 countsByYear W25166578402019 @default.
• W2516657840 countsByYear W25166578402020 @default.
• W2516657840 countsByYear W25166578402021 @default.
• W2516657840 countsByYear W25166578402022 @default.
• W2516657840 crossrefType "journal-article" @default.
• W2516657840 hasAuthorship W2516657840A5008600645 @default.
• W2516657840 hasAuthorship W2516657840A5009932633 @default.
• W2516657840 hasAuthorship W2516657840A5020272191 @default.
• W2516657840 hasAuthorship W2516657840A5021236744 @default.
• W2516657840 hasAuthorship W2516657840A5028663673 @default.
• W2516657840 hasAuthorship W2516657840A5041743198 @default.
• W2516657840 hasAuthorship W2516657840A5047331691 @default.
• W2516657840 hasAuthorship W2516657840A5056329041 @default.
• W2516657840 hasAuthorship W2516657840A5064358886 @default.
• W2516657840 hasAuthorship W2516657840A5068214093 @default.
• W2516657840 hasAuthorship W2516657840A5071312640 @default.
• W2516657840 hasBestOaLocation W25166578401 @default.
• W2516657840 hasConcept C104317684 @default.
• W2516657840 hasConcept C111599444 @default.
• W2516657840 hasConcept C121332964 @default.
• W2516657840 hasConcept C126322002 @default.
• W2516657840 hasConcept C135983454 @default.
• W2516657840 hasConcept C136229726 @default.
• W2516657840 hasConcept C142724271 @default.
• W2516657840 hasConcept C1491633281 @default.
• W2516657840 hasConcept C150903083 @default.
• W2516657840 hasConcept C153911025 @default.
• W2516657840 hasConcept C169274487 @default.
• W2516657840 hasConcept C207001950 @default.
• W2516657840 hasConcept C26291073 @default.
• W2516657840 hasConcept C2777807558 @default.
• W2516657840 hasConcept C2911091166 @default.
• W2516657840 hasConcept C49892992 @default.
• W2516657840 hasConcept C53227056 @default.
• W2516657840 hasConcept C553184892 @default.
• W2516657840 hasConcept C55493867 @default.
• W2516657840 hasConcept C62520636 @default.

• next